WO2005007082A3 - Treatment of chronic bacterial infection - Google Patents

Treatment of chronic bacterial infection Download PDF

Info

Publication number
WO2005007082A3
WO2005007082A3 PCT/US2004/016780 US2004016780W WO2005007082A3 WO 2005007082 A3 WO2005007082 A3 WO 2005007082A3 US 2004016780 W US2004016780 W US 2004016780W WO 2005007082 A3 WO2005007082 A3 WO 2005007082A3
Authority
WO
WIPO (PCT)
Prior art keywords
cryptic
calcium channel
bacterial infections
chronic bacterial
channel blockers
Prior art date
Application number
PCT/US2004/016780
Other languages
French (fr)
Other versions
WO2005007082A8 (en
WO2005007082A2 (en
Inventor
Anthony A Azenabor
Original Assignee
Wisys Technology Found Inc
Anthony A Azenabor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisys Technology Found Inc, Anthony A Azenabor filed Critical Wisys Technology Found Inc
Publication of WO2005007082A2 publication Critical patent/WO2005007082A2/en
Publication of WO2005007082A3 publication Critical patent/WO2005007082A3/en
Publication of WO2005007082A8 publication Critical patent/WO2005007082A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Abstract

The co-administration of antibiotics and calcium channel blockers in appropriate dose can produce a synergistic antimicrobial effect due to the ability of the calcium channel blocker to convert cryptic forms of chronic bacterial infections to a non-cryptic form. In particular, the effectiveness of L-type calcium channel blockers has been demonstrated with respect to converting chronic bacterial infections to non-cryptic forms. However, decrease or increase of intracellular calcium below or above certain levels results in a decrease in NO production. Since NO can produce desirable effects including, for example, desirable vascular changes and antimicrobial effects, it can be advantageous to control administration of calcium channel blockers to transform cryptic bacterial infections to non-cryptic forms while providing for desirable levels of NO production.
PCT/US2004/016780 2003-06-03 2004-05-27 Treatment of chronic bacterial infection WO2005007082A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47556203P 2003-06-03 2003-06-03
US60/475,562 2003-06-03
US85403104A 2004-05-26 2004-05-26
US10/854,031 2004-05-26

Publications (3)

Publication Number Publication Date
WO2005007082A2 WO2005007082A2 (en) 2005-01-27
WO2005007082A3 true WO2005007082A3 (en) 2005-05-26
WO2005007082A8 WO2005007082A8 (en) 2005-07-07

Family

ID=34594504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/016780 WO2005007082A2 (en) 2003-06-03 2004-05-27 Treatment of chronic bacterial infection

Country Status (1)

Country Link
WO (1) WO2005007082A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3017067B1 (en) 2013-07-03 2018-08-29 Qvella Corporation Methods of targeted antibiotic susceptibility testing
FR3033701B1 (en) * 2015-03-19 2021-01-15 Univ Claude Bernard Lyon NEW ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF INFLUENZA
FR3081325B1 (en) * 2018-05-23 2020-10-09 Univ Claude Bernard Lyon DILTIAZEM FOR USE IN THE TREATMENT OF MICROBIAL INFECTIONS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132119A (en) * 1989-07-31 1992-07-21 Massachusetts Institute Of Technology Treatment of hypertrophic wound healing disorders with calcium channel blockers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132119A (en) * 1989-07-31 1992-07-21 Massachusetts Institute Of Technology Treatment of hypertrophic wound healing disorders with calcium channel blockers

Also Published As

Publication number Publication date
WO2005007082A8 (en) 2005-07-07
WO2005007082A2 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
NZ701559A (en) Compositions comprising povidone-iodine
AU2001271545A1 (en) Promoting whole body health
WO2007059441A3 (en) Synergistic phytoceutical compositions
WO2002002063A8 (en) Promoting whole body health
WO2008041966A3 (en) Broad spectrum antibacterial compounds
ZA200807879B (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
WO2003091276A3 (en) Compositions and methods of use of peptides in combination with biocides and/or germicides
WO2005096990A3 (en) Novel modification of medical prostheses
WO2005046618A3 (en) Methods of treating eczema
WO2009040445A3 (en) Arabinoxylo-oligosaccharides useful against gastrointestinal infections
EP2279662A3 (en) 5,7,4'-trihydroxy-3',5'-dimethoxyflavone as an antibacterial agent
WO2005081904A3 (en) Antimicrobial carbohydrates and methods of using same
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2007131047A3 (en) Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds
WO2007061942A3 (en) Compositions for disrupting and inhibiting reconstitution of wound biofilm
EP1050300A3 (en) Selective antibacterial composition
EP3760626A4 (en) Novel compound and composition for preventing, ameliorating, or treating fibrosis or nonalcoholic steatohepatitis comprising same as active ingredient
EP3305305A3 (en) Silicate containing compositions and methods of treatment
MX2022015601A (en) Compound for the treatment of coronaviral infections.
WO2008090209A3 (en) Use of glucopyranosyloxy- pyrazoles for preventing and treating neurodegenerative disorders
WO2005007082A8 (en) Treatment of chronic bacterial infection
EP1060745A3 (en) A composition and method for treating bacterial infection
WO2009024121A3 (en) Soft-tissue implant having antibacterial effect
WO2008018111A3 (en) Composition containing cranberry (vaccinium macrocarpon) and lactoferrin for the prevention and treatment of urinary tract infections
AU2003250522A1 (en) Compositions and methods for treatment and prophylaxis of infections caused by gram positive bacteria

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 04/2005 UNDER (30) REPLACE "NOT FURNISHED" BY "10/854,031"

122 Ep: pct application non-entry in european phase